Platelet-derived microparticles and platelet function profile in children with congenital heart disease

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 4, 2013, Pages 424-432

  Ismail, Eman Abdel Rahman ^a   Youssef, Omneya Ibrahim ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

congenital heart disease; P selectin; platelet microparticles

Indexed keywords

D DIMER; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HEMOGLOBIN; PADGEM PROTEIN; VON WILLEBRAND FACTOR;

ACYANOTIC CONGENITAL HEART DISEASE; ARTICLE; BLOOD CLOTTING DISORDER; CHILD; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; CYANOTIC HEART DISEASE; ENDOTHELIAL DYSFUNCTION; FEMALE; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HUMAN; MALE; PATHOGENESIS; PLATELET MICROPARTICLE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

CONGENITAL HEART DISEASE; P-SELECTIN; PLATELET MICROPARTICLES;

BLOOD PLATELETS; CELL-DERIVED MICROPARTICLES; CHILD; CHILD, PRESCHOOL; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; MALE; PLATELET ACTIVATION; PLATELET AGGREGATION;

EID: 84879910220     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029612456733     Document Type: Article

References (58)

1. Zipes DP, Libby P, Bonow RO, Braunwald E Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 8 th ed. St. Louis, MO: WB Saunders; 2007. St. Louis, MO: WB Saunders ; 2007 :
2. Hartmann RC. A hemorrhagic disorder occurring in patients with cyanotic congenital heart disease. Bull Johns Hopkins Hosp. 1952 ; 91 (1). 49-67
3. Olgun N, Uysal KM, Irken G, et al. Platelet activation in congenital heart diseases. Acta Paediatr Jpn. 1997 ; 39 (5). 566-569
4. Perloff JK, Rosove MH, Sietsema KE, Territo MC Congenital Heart Disease in Adults. 2 nd ed. Philadelphia, PA: WB Saunders; 1998:199-226. Perloff JK Child JS, ed. Philadelphia, PA: WB Saunders ; 1998: 199-226.
5. Levin E, Wu J, Devine DV, et al. Hemostatic parameters and platelet activation marker expression in cyanotic and acyanotic pediatric patients undergoing cardiac surgery in the presence of tranexamic acid. Thromb Haemost. 2000 ; 83 (1). 54-59
6. Kajimoto H, Nakazawa M, Murasaki K, et al. Increased thrombogenesity in patients with cyanotic congenital heart disease. Circ J. 2007 ; 71 (6). 948-953
7. Horigome H, Hiramatsu Y, Shigeta O, Nagasawa T, Matsui A. Overproduction of platelet microparticles in cyanotic congenital heart disease with polycythemia. J Am Coll Cardiol. 2002 ; 39 (6). 1072-1077
8. Sakamaki F, Kyotani S, Nagaya N, et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation. 2000 ; 102 (22). 2720-2725
9. Hrachovinová I, Cambien B, Hafezi-Moghadam A, et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med. 2003 ; 9 (8). 1020-1025
10. Koyama H, Maeno T, Fukumoto S, et al. Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation. 2003 ; 108 (5). 524-529
11. Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2007 ; 21 (3). 157-171
12. Rozmyslowicz T, Majka M, Kijowski J, et al. Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV. AIDS. 2003 ; 17 (1). 33-42
13. Flaumenhaft R, Dilks JR, Richardson J, et al. Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. Blood. 2009 ; 113 (5). 1112-1121
14. Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol. 1999 ; 30 (2). 111-142
15. Boulanger CM, Amabile N, Tedgui A. Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. Hypertension. 2006 ; 48 (2). 180-186
16. Holme PA, Solum NO, Brosstad F, Roger M, Abdelnoor M. Demonstration of platelet-derived microvesicles in blood from patients with activated coagulation and fibrinolysis using a filtration technique and Western blotting. Thromb Haemost. 1994 ; 72 (5). 666-671
17. Gawaz M, Neumann FJ, Ott I, Schiessler A, Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation. 1996 ; 93 (2). 229-237
18. Katopodis JN, Kolodny L, Jy W, et al. Platelet microparticles and calcium homeostasis in acute coronary ischemias. Am J Hematol. 1997 ; 54 (2). 95-101
19. Nomura S, Suzuki M, Katsura K, et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis. 1995 ; 116 (2). 235-240
20. Habib A, Kunzelmann C, Shamseddeen W. Elevated levels of circulating procoagulant microparticles in patients with β-thalassemia intermedia. Haematologica. 2008 ; 93 (6). 941-942
21. van Beers EJ, Schaap MCL, Berkmans RJ, et al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica. 2009 ; 94 (11). 1513-1519
22. Ataga KI. Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica. 2009 ; 94 (11). 1481-1484
23. Rectenwald JE, Myers Jr, Hawley AE, et al. d-Dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. A pilot study. Thromb Haemost. 2005 ; 94 (6). 1312-1317
24. Holme PA, Orvim U, Hamers MJ, et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arteriosclerosis Thromb Vasc Biol. 1997 ; 17 (4). 646-653
25. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study. J Invasive Cardiol. 2004 ; 16 (6). 325-329
26. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res. 2005 ; 115 (1-2). 101-108
27. Gurbel PA, Serebruany VL, Shustov AR, et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. J Am Coll Cardiol. 1998 ; 31 (7). 1466-1473
28. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003 ; 107 (23). 2908-2913
29. Jeong YH, Hwang JY, Kim IS, et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv. 2010 ; 3 (1). 17-26
30. Shigeta O, Kojima H, Jikuya T, et al. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. Circulation. 1997 ; 96 (2). 569-574
31. Chen Y, Davis-Gorman G, Watson RR, McDonagh PF. Platelet CD62p expression and microparticle in murine acquired immune deficiency syndrome and chronic ethanol consumption. Alcohol Alcohol. 2003 ; 38 (1). 25-30
32. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005 ; 54 (8). 2430-2435
33. Kern FK, Morana NJ, Sears JJ, Hickey PR. Coagulation defects in neonates during cardiopulmonary bypass. Ann Thorac Surg. 1992 ; 54 (3). 541-546
34. Rinder CS, Gaal D, Student LA, Smith BR. Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1994 ; 107 (1). 280-288
35. Schulman SR, Kern FH, Greeley WJ Critical Heart Disease in Infants and Children. DG Nichols DE Cameron WJ Greeley DG Lappe Ungerleider RM RC Wetzel, ed. St Louis, MO: Mosby-Year Book ; 1995: 401-413.
36. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost. 2009 ; 101 (3). 439-451
37. Goel M, Shome DK, Singh ZN, Bhattacharjee J, Khalil A. Haemostatic changes in children with cyanotic and acyanotic congenital heart disease. Indian Heart J. 2000 ; 52 (5). 559-563
38. Lill MC, Perloff JK, Child JS. Pathogenesis of thrombocytopenia in cyanotic congenital heart disease. Am J Cardiol. 2006 ; 98 (2). 254-258
39. Cattaneo M. The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood. 2011 ; 117 (7). 2102-2112
40. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004 ; 113 (3). 340-345
41. Adatia I, Barrow SE, Stratton P, Ritter JM, Haworth SG. Abnormalities in the biosynthesis of thromboxane A2 and prostacyclin in children with cyanotic congenital heart disease. Br Heart J. 1993 ; 69 (2). 179-182
42. Horigome H, Murakami T, Isobe T, Nagasawa T, Matsui A. Soluble P-selectin and thrombomodulin-protein C-Protein S pathway in cyanotic congenital heart disease with secondary erythrocytosis. Thromb Res. 2003 ; 112 (4). 223-227
43. Merten M, Chow T, Hellums JD, Thiagarajan P. A new role for P selectin in shear-induced platelet aggregation. Circulation. 2000 ; 102 (17). 2045-2050
44. Horvath B, Hegedus D, Szapary L, et al. Measurement of von Willebrand factor as the marker of endothelial dysfunction in vascular diseases. Exp Clin Cardiol. 2004 ; 9 (1). 31-34
45. Oechslin E, Kiowski W, Schindler R, Bernheim A, Julius B, Brunner-La Rocca HP. Systemic endothelial dysfunction in adults with cyanotic congenital heart disease. Circulation. 2005 ; 112 (8). 1106-1112
46. Levin E, Wu J, Devine DV, et al. Hemostatic parameters and platelet activation marker expression in cyanotic and acyanotic pediatric patients undergoing cardiac surgery in the presence of tranexamic acid. Thromb Haemost. 2000 ; 83 (1). 54-59
47. Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A. 1996 ; 93 (21). 11877-11882
48. Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J. 2003 ; 24 (24). 2166-2179
49. Nurden AT, Poujol C, Durrieu-Jais C, Nurden P. Platelet glycoprotein IIb/IIIa inhibitors: basic and clinical aspects. Arterioscler Thromb Vasc Biol. 1999 ; 19 (12). 2835-2840
50. Kozek-Langenecker SA, Mohammad SF, Masaki T, Kamerath C, Cheung AK. The effects of heparin, protamine, and heparinase 1 on platelets in vitro using whole blood flow cytometry. Anesth Analg. 2000 ; 90 (4). 808-812
51. Jacoby RC, Owings JT, Holmes J, Battistella FD, Gosselin RC, Paglieroni TG. Platelet activation and function after trauma. J Trauma. 2001 ; 51 (4). 639-647
52. Merten M, Thiagarajan P. P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation. 2000 ; 102 (16). 1931-1936
53. Murakami T, Komiyama Y, Masuda M, et al. Flow cytometric analysis of platelet activation markers CD62P and CD63 in patients with coronary heart disease. Eur J Clin Invest. 1996 ; 26 (11). 996-1003
54. Holme PA, Müller F, Solum NO, Brosstad F, Frøland SS, Aukrust P. Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J. 1998 ; 12 (1). 79-89
55. Pattanapanyasat K, Gonwong S, Chaichompoo P, et al. Activated platelet-derived microparticles in thalassaemia. Br J Haematol. 2007 ; 136 (3). 462-471
56. Morel O, Morel N, Freyssinet JM, Toti F. Platelet microparticles and vascular cells interactions: a checkpoint between the haemostatic and thrombotic responses. Platelets. 2008 ; 19 (1). 9-23
57. Candice KS, John TG, Eli K, Michelle AH. Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol. 2003 ; 42 (11). 1982-1987
58. Owens AP, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res. 2011 ; 108 (10). 1284-1297